21 – 30 of 55
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
(
- Contribution to journal › Article
-
Mark
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
(
- Contribution to journal › Article
-
Mark
In vivo CYP3A activity and pharmacokinetics of imatinib in relation to therapeutic outcome in chronic myeloid leukemia patients.
(
- Contribution to journal › Article
- 2015
-
Mark
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
(
- Contribution to journal › Article
- 2014
-
Mark
Epidermal Growth Factor-like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer.
(
- Contribution to journal › Article
-
Mark
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines.
(
- Contribution to journal › Article
- 2013
-
Mark
Physical activity during and after adjuvant chemotherapy in patients with breast cancer.
(
- Contribution to journal › Article
-
Mark
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial
(
- Contribution to journal › Article
-
Mark
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
(
- Contribution to journal › Article